EU CHMP Backs Novo’s FREHEMGO for Monthly Dosing

This is a regulatory milestone for a first-in-class mechanism, not just another label expansion: a FVIIIa mimetic enabling monthly dosing could reset convenience benchmarks in hemophilia care, where prophylaxis frequency remains a major adherence hurdle. The recommendation matters most for Novo's competitive standing in a field where dosing interval is a key differentiator, and for patients weighing routine burden against protection. The open questions are whether the monthly profile holds up in real-world use and how quickly national reimbursement follows the staggered EU launch timeline.